Positive kidney cancer data could help Welireg reach full potential

18 August 2023
merck_msd_rchsolutions_big

New Jersey, USA-based Merck & Co (NYSE: MRK) has reported positive top-line data from a trial of its oral HIF-2α blocker Welireg (belzutifan).

In 2021, Welireg was  approved in the USA for the treatment of von Hippel-Lindau (VHL) disease, a rare kidney condition, with quarterly sales growing to the low tens of millions.

Merck is running the LITESPARK-005 trial with the goal of expanding the label to include the treatment of advanced renal cell carcinoma (RCC) as a later-line treatment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical